Caris Life Sciences, Inc.

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.

prnewswire.com - 2026-07-16 08:30:00

IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology for this disease.

prnewswire.com - 2026-07-14 08:30:00

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologies IRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection.

prnewswire.com - 2026-07-01 08:30:00

ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewide contract with the Virginia Information Technologies Agency (VITA) to provide Security Operations Center (SOC) services to local government entities across the Commonwealth.

globenewswire.com - 2026-06-24 09:07:00

ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.

globenewswire.com - 2026-06-17 09:06:00

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.

prnewswire.com - 2026-06-16 08:30:00

Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and positive free cash flow. CAI's genomic database of over one million cases underpins future products like Caris Detect, offering a potential competitive edge. At 5x EV/Sales, CAI trades at a discount to peers despite superior growth and profitability, further supported by a $100M buyback.

seekingalpha.com - 2026-06-12 07:57:50

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 15:48:32

IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

prnewswire.com - 2026-06-08 08:30:00

Calgary, Alberta--(Newsfile Corp. - May 28, 2026) - Capitan Investment Ltd. (TSXV: CAI) (the "Corporation") announces that it has elected to adopt semi-annual financial reporting in reliance on the Coordinated Blanket Order 51 - 933 Exemption to Permit Semi-Annual Reporting for Certain Venture Issuers.

newsfilecorp.com - 2026-05-28 14:11:00

Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma IRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-negative breast cancer.

prnewswire.com - 2026-05-26 08:30:00

ALLENTOWN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, with more than 40 years of expertise delivering technology solutions to public sector and commercial organizations, announced strategic partnerships with Amazon Web Services (AWS) and Microsoft, alongside collaboration with Anthropic, Databricks and LMNTRIX.

globenewswire.com - 2026-05-20 09:02:00

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris

gurufocus.com - 2026-05-15 09:00:00

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing.

prnewswire.com - 2026-05-15 08:30:00

Caris Life Sciences NASDAQ: CAI executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June.

marketbeat.com - 2026-05-13 05:06:51

Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 15:40:51

Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination IRVING, Texas, May 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembrolizumab.

prnewswire.com - 2026-05-11 12:15:00

IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State. Caris Assure is a blood‑based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample.

prnewswire.com - 2026-05-08 16:05:00

Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 10:41:17

Revenue growth of 79% driven by strong performance in molecular profiling services IRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Reported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.

prnewswire.com - 2026-05-07 16:05:00

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the launch of Caris MI Clarity™, the first prognostic test designed to deliver insight into both early and late distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer at the time of diagnosis. Results are typically provided to the ordering physician within 3 business days of receiving the tissue sample, compared to a few weeks for historical tests.

prnewswire.com - 2026-05-05 08:30:00

IRVING, Texas, May 4, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that Caris ChromoSeq™ has received MolDX approval, a key milestone supporting broader clinical access to Caris' comprehensive whole genome tumor profiling assay for myeloid malignancies. The Molecular Diagnostic Services (MolDX) program, administered by Palmetto GBA on behalf of the Centers for Medicare & Medicaid Services (CMS), evaluates molecular diagnostic tests to determine whether they demonstrate clinical validity and utility to support coverage and reimbursement decisions.

prnewswire.com - 2026-05-04 08:30:00

Calgary, Alberta--(Newsfile Corp. - May 1, 2026) - Capitan Investment Ltd. (TSXV: CAI) ("Capitan") announces that effective April 30, 2026, Liqun Hao was appointed the Chief Financial Officer of Capitan and Panwen Gao was appointed the Chair of the board of directors of Capitan.

newsfilecorp.com - 2026-05-01 12:07:00

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 29, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the development and peer-reviewed validation of a new predictive signature to inform therapy selection in glioblastoma (GBM) patients. The study, published in Neuro-Oncology Advances, describes the development and evaluation of the model in a cohort of more than 5,800 GBM patients.

prnewswire.com - 2026-04-29 08:30:00

IRVING, Texas, April 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The BofA Securities 2026 Health Care Conference will be held on May 12-14, 2026, in Las Vegas, Nevada.

prnewswire.com - 2026-04-24 08:30:00

IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.

prnewswire.com - 2026-04-20 08:30:00

IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance®  (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research.

prnewswire.com - 2026-04-17 08:30:00